Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them

A process for the preparation of compound of formula (III) its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives;

• the ring A fused to the ring containing X and N represents a 5-6 members carbocyclic structure which may optionally be substituted;
• the ring A may be saturated or contain one or more double bonds or may be aromatic;
• X represents a heteroatom selected from oxygen, or sulfur;
• Ar represents an optionally substituted divalent single or fused aromatic or heterocyclic group;
• R.sup.5 forms a bond together with R.sup.6 ;
• R.sup.7 represents hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups;
• R.sup.8 represents hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups;
• n is an integer ranging from 1-4 and m is an integer 0 or 1;
• which comprises:
• a) reacting a compound of formula (IIIa) ##STR50## where all symbols are as defined above with a compound of formula (IIIb) ##STR51## where R.sup.11 may be a lower alkyl group and R.sup.7 and R.sup.8 are as defined above;
• b) reacting a compound of formula (IIIa) ##STR52## where all symbols are as defined above with a compound of formula (IIIc) ##STR53## where R.sup.6 represents hydrogen atom and R.sup.7 and R.sup.8 are as defined above followed by dehydration;
• c) reacting a compound of formula (IIIe) ##STR54## where L.sup.1 represents a leaving group and all other symbols are as defined above with a compound of formula (IIId) ##STR55## where R.sup.7, R.sup.8 and Ar are as defined above;
• d) reacting a compound of formula (IIIg) ##STR56## where all symbols are as defined above with a compound of general formula (IIIf) ##STR57## where all symbols are as defined above and L.sup.1 is a leaving group;
• e) reacting a compound of formula (IIIh) ##STR58## where all symbols are as defined above with a compound of formula (IIId) ##STR59## where all symbols are as defined above and if needed;
• f) converting the compounds of formula (III) obtained in any of the processes described above into pharmaceutically acceptable salts, or pharmaceutically acceptable solvates.

A process for the preparation of compound of formula (I) ##STR72## its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives;

• the ring A fused to the ring containing X and N represents 5-6 membered carbocyclic structure containing carbon atoms which may optionally be substituted;
• the ring A may be saturated or contain one or more double bonds or may be aromatic;
• X represents a heteroatom selected from oxygen, or sulfur;
• Ar represents an optionally substituted divalent single or fused aromatic or heterocyclic group;
• R.sup.5 represents hydrogen, hydroxy, alkoxy, halogen, lower alkyl, optionally substituted aralkyl group or forms a bond together with the adjacent group R.sup.6 ;
• R.sup.6 represents hydrogen, hydroxy, alkoxy, halogen, lower alkyl group, acyl, optionally aralkyl or R.sup.6 forms a bond together with R.sup.5 ;
• R.sup.7 represents hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups;
• R.sup.8 represents hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups;
• Y represents NR.sup.10, where R.sup.10 represents hydrogen, alkyl, aryl, hydroxyalkyl or aralkyl groups or R.sup.8 and R.sup.10 together may form a 5 or 6 membered cyclic structure containing carbon atoms, which may optionally contain one or more heteroatoms selected from oxygen, sulfur or nitrogen;
• n is an integer ranging from 1-4 and m is an integer 0 or 1;
• which comprises
• a) reacting a compound of formula (I) where all the symbols are as defined above and Y represents oxygen with appropriate amines and if needed;
• b) converting the compounds of formula (I) obtained above into pharmaceutically acceptable salts, or pharmaceutically acceptable solvates.